These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 30903281)

  • 1. Bevacizumab-containing regimen in relapsed/progressed brain tumors: a single-institution experience.
    Schiavetti A; Varrasso G; Mollace MG; Dominici C; Ferrara E; Papoff P; Di Biasi C
    Childs Nerv Syst; 2019 Jun; 35(6):1007-1012. PubMed ID: 30903281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
    Gururangan S; Fangusaro J; Poussaint TY; McLendon RE; Onar-Thomas A; Wu S; Packer RJ; Banerjee A; Gilbertson RJ; Fahey F; Vajapeyam S; Jakacki R; Gajjar A; Goldman S; Pollack IF; Friedman HS; Boyett JM; Fouladi M; Kun LE
    Neuro Oncol; 2014 Jan; 16(2):310-7. PubMed ID: 24311632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
    Gururangan S; Chi SN; Young Poussaint T; Onar-Thomas A; Gilbertson RJ; Vajapeyam S; Friedman HS; Packer RJ; Rood BN; Boyett JM; Kun LE
    J Clin Oncol; 2010 Jun; 28(18):3069-75. PubMed ID: 20479404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience.
    Aguilera D; Mazewski C; Fangusaro J; MacDonald TJ; McNall-Knapp RY; Hayes LL; Kim S; Castellino RC
    Childs Nerv Syst; 2013 Apr; 29(4):589-96. PubMed ID: 23296323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab in recurrent high-grade pediatric gliomas.
    Narayana A; Kunnakkat S; Chacko-Mathew J; Gardner S; Karajannis M; Raza S; Wisoff J; Weiner H; Harter D; Allen J
    Neuro Oncol; 2010 Sep; 12(9):985-90. PubMed ID: 20363768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
    Okada K; Yamasaki K; Tanaka C; Fujisaki H; Osugi Y; Hara J
    Jpn J Clin Oncol; 2013 Nov; 43(11):1073-9. PubMed ID: 24002900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study.
    Gururangan S; Fangusaro J; Young Poussaint T; Onar-Thomas A; Gilbertson RJ; Vajapeyam S; Gajjar A; Goldman S; Friedman HS; Packer RJ; Boyett JM; Kun LE; McLendon R
    Neuro Oncol; 2012 Nov; 14(11):1404-12. PubMed ID: 23019233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.
    van den Bent MJ; Klein M; Smits M; Reijneveld JC; French PJ; Clement P; de Vos FYF; Wick A; Mulholland PJ; Taphoorn MJB; Lewis J; Weller M; Chinot OL; Kros JM; de Heer I; Verschuere T; Coens C; Golfinopoulos V; Gorlia T; Idbaih A
    Lancet Oncol; 2018 Sep; 19(9):1170-1179. PubMed ID: 30115593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of health related quality of life in patients with recurrent glioma treated with bevacizumab plus daily temozolomide as the salvage therapy.
    Liu Y; Feng F; Ji P; Liu B; Ge S; Yang C; Lou M; Liu J; Li B; Gao G; Qu Y; Wang L
    Clin Neurol Neurosurg; 2018 Jun; 169():64-70. PubMed ID: 29631109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metronomic Maintenance With Weekly Vinblastine After Induction With Bevacizumab-Irinotecan in Children With Low-grade Glioma Prevents Early Relapse.
    Roux C; Revon-Rivière G; Gentet JC; Verschuur A; Scavarda D; Saultier P; Appay R; Padovani L; André N
    J Pediatr Hematol Oncol; 2021 Jul; 43(5):e630-e634. PubMed ID: 33235152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).
    Fangusaro J; Gururangan S; Poussaint TY; McLendon RE; Onar-Thomas A; Warren KE; Wu S; Packer RJ; Banerjee A; Gilbertson RJ; Jakacki R; Gajjar A; Goldman S; Pollack IF; Friedman HS; Boyett JM; Kun LE; Fouladi M
    Cancer; 2013 Dec; 119(23):4180-7. PubMed ID: 24104527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.
    Modak S; Kushner BH; Basu E; Roberts SS; Cheung NK
    Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28111925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study.
    Le Teuff G; Castaneda-Heredia A; Dufour C; Jaspan T; Calmon R; Devos A; McHugh K; Leblond P; Frappaz D; Aerts I; Zwaan CM; Ducassou S; Chastagner P; Verschuur A; Corradini N; Casanova M; Rubie H; Riccardi R; Le Deley MC; Vassal G; Geoerger B;
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28032. PubMed ID: 31595663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irinotecan, vincristine, cisplatin, cyclophosphamide, and etoposide for refractory or relapsed medulloblastoma/PNET in pediatric patients.
    Kim H; Kang HJ; Lee JW; Park JD; Park KD; Shin HY; Ahn HS
    Childs Nerv Syst; 2013 Oct; 29(10):1851-8. PubMed ID: 23748464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma.
    Grill J; Massimino M; Bouffet E; Azizi AA; McCowage G; Cañete A; Saran F; Le Deley MC; Varlet P; Morgan PS; Jaspan T; Jones C; Giangaspero F; Smith H; Garcia J; Elze MC; Rousseau RF; Abrey L; Hargrave D; Vassal G
    J Clin Oncol; 2018 Apr; 36(10):951-958. PubMed ID: 29412784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial.
    Levy AS; Krailo M; Chi S; Villaluna D; Springer L; Williams-Hughes C; Fouladi M; Gajjar A
    Pediatr Blood Cancer; 2021 Aug; 68(8):e29031. PubMed ID: 33844469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen.
    Parekh C; Jubran R; Erdreich-Epstein A; Panigrahy A; Bluml S; Finlay J; Dhall G
    J Neurooncol; 2011 Jul; 103(3):673-80. PubMed ID: 21038110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
    Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
    Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low-grade glioma.
    Zhukova N; Rajagopal R; Lam A; Coleman L; Shipman P; Walwyn T; Williams M; Sullivan M; Campbell M; Bhatia K; Gottardo NG; Hansford JR
    Cancer Med; 2019 Jan; 8(1):40-50. PubMed ID: 30569607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients.
    de Marcellus C; Tauziède-Espariat A; Cuinet A; Pasqualini C; Robert MP; Beccaria K; Puget S; Boddaert N; Figarella-Branger D; De Carli E; Bourdeaut F; Leblond P; Fouyssac F; Andre N; Bertozzi AI; Butel T; Dufour C; Valteau-Couanet D; Varlet P; Grill J
    J Neurooncol; 2022 Apr; 157(2):355-364. PubMed ID: 35239111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.